corgenix Message Board - Msg: 24097036

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : corgenix

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: RikRichter	11/30/2007 10:15:34 AM
	of 191

Business Gazette.Net Maryland Community Newspapers Online Friday, Nov. 30, 2007 MedImmune drug targets prostate and other cancers Biotech also developing treatments for arthritis and asthma by Steve Berberich \| Staff Writer ...Another Maryland company, Northwest Biotherapeutics Inc. of Bethesda, has received federal approval to conduct a phase 3 clinical trial of its DCVax-Prostate to treat late-stage prostate cancer. Data from an earlier trial suggested that DCVax-Prostate might induce an immune response. Clinical data obtained in the ongoing trial show possible delayed progression of disease, especially in patients with no metastatic effect at the start of the trial. Northwest’s main research and development facilities are in Bothell, Wash. Its manufacturing partner is Cognate BioServices Inc. of Baltimore, which is majority owned by Toucan Partners LLC of Bethesda...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next